The Patent Finder

PRG S&TECH Inc.

5 patents currently held · Updated Nov 14, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Aug 2032
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Aug 2, 2027
    The maintenance fee for Pharmaceutical composition for treating aging-associated diseases, containing progerin expression inhibitor as active ingredient, and screening method of said progerin expression inhibitor (US 9,249,153) comes due Aug 2, 2027. Unpaid by Feb 2, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 16, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 5 of 5

PatentTitleStatus Expires Confidence
US 9,249,153Pharmaceutical composition for treating aging-associated diseases, containing progerin expression inhibitor as active ingredient, and screening method of said progerin expression inhibitor
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,008,332Pharmaceutical composition for preventing or treating aging-related diseases containing decursin derivative as active ingredient
In force
 · From the USPTO record
In forceFrom the USPTO record
US 12,391,704Method for synthesizing decursin derivative
In force
 · From the USPTO record
In forceFrom the USPTO record
US 12,448,393Use of novel compound, for preventing, improving or treating amyotrophic lateral sclerosis
In force
 · From the USPTO record
In forceFrom the USPTO record
US 12,741,946Composition for Prevention or Treatment of Neurofibromatosis Type 2 Syndrome
In force
 · High confidence
In forceHigh confidence

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

3 pending · 1 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited